Curcumin attenuates amyloid-β-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3β signaling pathway

References

• Huang HC, Jiang ZF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease. J Alzheimers Dis 2009;16:15–27
   PubMed Web of Science ®Google Scholar
• Huang HC, Jiang ZF. Amyloid-beta protein precursor family members: a review from homology to biological function. J Alzheimers Dis 2011;26:607–26
   PubMedGoogle Scholar
• Smith RP, Higuchi DA, Broze GJ, Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990;248:1126–8
   PubMed Web of Science ®Google Scholar
• Small DH, Clarris HL, Williamson TG, et al. Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. J Alzheimers Dis 1999;1:275–85
   PubMedGoogle Scholar
• Seabrook GR, Smith DW, Bowery BJ, et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 1999;38:349–59
   PubMed Web of Science ®Google Scholar
• Gralle M, Ferreira ST. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog Neurobiol 2007;82:11–32
   PubMed Web of Science ®Google Scholar
• Rama N, Goldschneider D, Corset V, et al. Amyloid precursor protein regulates netrin-1-mediated commissural axon outgrowth. J Biol Chem 2012;287:30014–23
   PubMed Web of Science ®Google Scholar
• García-Sierra F, Jarero-Basulto JJ, Kristofikova K, et al. Ubiquitin is associated with early truncation of tau protein at aspartic acid421 during the maturation of neurofibrillary tangles in Alzheimer’s disease. Brain Pathol 2012;22:240–50
   PubMedGoogle Scholar
• Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992;8(1):159–68
   PubMed Web of Science ®Google Scholar
• Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95–130
   PubMed Web of Science ®Google Scholar
• Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011;31:1688–92
   PubMed Web of Science ®Google Scholar
• Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012;181:1426–35
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184–5
   PubMed Web of Science ®Google Scholar
• Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 2012;1:18
   PubMedGoogle Scholar
• Yanagisawa D, Taguchi H, Yamamoto A, et al. Curcuminoid binds to amyloid-beta1-42 oligomer and fibril. J Alzheimers Dis 2011;24:33–42
   PubMed Web of Science ®Google Scholar
• Mutsuga M, Chambers JK, Uchida K, et al. Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer’s brain. J Vet Med Sci 2012;74:51–7
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892–901
   PubMed Web of Science ®Google Scholar
• Zhang C, Browne A, Child D, Tanzi RE. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 2010;285:28472–80
   PubMed Web of Science ®Google Scholar
• Liu H, Li Z, Qiu D, et al. The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 2010;485:83–8
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin H, Wang L, et al. Curcumin as a potential treatment for Alzheimer’s disease: a study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein. Am J Chin Med 2013;41:59–70
   PubMed Web of Science ®Google Scholar
• Huang HC, Chang P, Dai XL, Jiang ZF. Protective effects of curcumin on amyloid-beta-induced neuronal oxidative damage. Neurochem Res 2012;37:1584–97
   PubMed Web of Science ®Google Scholar
• Huang HC, Xu K, Jiang ZF. Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta. J Alzheimers Dis 2012;32:981–96
   PubMed Web of Science ®Google Scholar
• Flugel D, Gorlach A, Kietzmann T. GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. Blood 2012;119:1292–301
   PubMed Web of Science ®Google Scholar
• Itoh S, Saito T, Hirata M, et al. GSK-3alpha and GSK-3beta proteins are involved in early stages of chondrocyte differentiation with functional redundancy through RelA protein phosphorylation. J Biol Chem 2012;287:29227–36
   PubMedGoogle Scholar
• Durairajan SS, Liu LF, Lu JH, et al. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer’s disease transgenic mouse model. Neurobiol Aging 2012;33:2903–19
   PubMed Web of Science ®Google Scholar
• Terwel D, Muyllaert D, Dewachter I, et al. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 2008;172:786–98
   PubMed Web of Science ®Google Scholar
• Dominguez JM, Fuertes A, Orozco L, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012;287:893–904
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG. Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine – searching for the connections. Br J Pharmacol 2012;167:324–52
   PubMed Web of Science ®Google Scholar
• den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003;46:1604–10
   PubMed Web of Science ®Google Scholar
• Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nat Clin Pract Neurol 2006;2:159–66
   PubMedGoogle Scholar
• de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 2012;9:35–66
   PubMedGoogle Scholar
• Liu S, Liu Y, Hao WL, et al. TLR2 is a primary receptor for Alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J. Immunol 2012;188:1098–107
   PubMed Web of Science ®Google Scholar
• Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010;30:11938–50
   PubMed Web of Science ®Google Scholar
• Alberdi E, Sanchez-Gomez MV, Cavaliere F, et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010;47:264–72
   PubMed Web of Science ®Google Scholar
• Small DH, Gasperini R, Vincent AJ, et al. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 2009;16:225–33
   PubMedGoogle Scholar
• Mota SI, Ferreira IL, Pereira C, et al. Amyloid-beta peptide 1-42 causes microtubule deregulation through N-methyl-D-aspartate receptors in mature hippocampal cultures. Curr Alzheimer Res 2012;9:844–56
   Google Scholar
• Kervern M, Angeli A, Nicole O, et al. Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-beta peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimers Dis 2012;32(1):183–96
   PubMedGoogle Scholar
• Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011;27:1375–83
   PubMed Web of Science ®Google Scholar
• Mohamed A, Posse de Chaves E. Abeta internalization by neurons and glia. Int J Alzheimers Dis 2011;2011:127984
   PubMedGoogle Scholar
• Gu XM, Huang HC, Jiang ZF. Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer’s disease. Neurosci Bull 2012;28:631–40
   PubMedGoogle Scholar
• Yan SD, Fu J, Soto C, et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease. Nature 1997;389:689–95
   PubMed Web of Science ®Google Scholar